<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-128512</identifier>
<setSpec>0214-9168</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Efficacy studies</dc:title>
<dc:description xml:lang="en">Pravafenix® is a fi xed-dose combination of 40 mg of pravastatin and 160 mg of fenofi brate. The rationale behind the use of Pravafenix® is based on the increased residual cardiovascular risk observed in high risk patients with hypertriglyceridemia and/or low HDL cholesterol levels despite treatment with statins in monotherapy. In this article, we review the available evidence on the clinical effi cacy of Pravafenix®, which shows complementary benefi ts in the overall lipid profi le of high risk patients with mixed dyslipidemia not controlled with 40-mg pravastatin or 20-mg simvastatin (AU)</dc:description>
<dc:creator>Flores-Le Roux, Juana A</dc:creator>
<dc:creator>Pedro-Botet, Juan</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Pravafenix® es una combinación a dosis fija de 40 mg de pravastatina y 160 mg de fenofibrato. La justificación para el uso de Pravafenix® se basa en el aumento del riesgo cardiovascular residual observado en los pacientes de alto riesgo con hipertrigliceridemia y/o concentraciones bajas de colesterol unido a lipoproteínas de alta densidad a pesar del tratamiento con estatinas en monoterapia. A continuación, se revisa la evidencia disponible de la eficacia clínica de Pravafenix®, que muestra beneficios complementarios en el perfil lipídico global de los pacientes de alto riesgo con dislipemia mixta no controlada con pravastatina 40 mg o simvastatina 20 mg (AU)</dc:description>
<dc:source>Clín. investig. arterioscler. (Ed. impr.);26(supl.1): 17-19, jul. 2014. tab</dc:source>
<dc:identifier>ibc-128512</dc:identifier>
<dc:title xml:lang="es">Estudios de eficacia</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d11781^s22073</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d33014^s22073</dc:subject>
<dc:subject>^d54030^s22073</dc:subject>
<dc:subject>^d50514^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d7130^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201407</dc:date>
</metadata>
</record>
</ibecs-document>
